67 results about "Bacteroides salyersiae" patented technology

The invention relates to the field of microbiological preparations, and particularly discloses an inactivated bacteroid micro-ecological preparation and a preparation method of the inactivated bacteroid micro-ecological preparation. The preparation uses inactivated bacteroid and fermentation concentrate as the main ingredients; and the inactivated bacterioid micro-ecological preparation has the efficacies of resisting bacteria, diminishing inflammation, adjusting the microbial community of the gastrointestinal tract, preventing gastrointestinal diseases of human and animals and the like, and has the characteristics of quick operation, high safety, use convenience and the like. The inactivated bacteroid micro-ecological preparation is used for disease prevention and health of human and animals, has a good practical application value, and has a remarkable effect especially when being applied to animal feeds, so that the probiotic inactivated micro-ecological preparation is a technology worth of population.

The invention relates to a method for fermenting and producing fermented vinegar by using various probiotics. The method is characterized in that in an alcohol fermentation stage, cultured probiotics, which are suitable for the growth of amylase and yeast, of aspergillus niger, aspergillus oryzae and anaerobic bacteroides are added; in an acetic fermentation stage, cultured probiotics, which are suitable for the growth of acetic acid bacteria under 38-46 DEG C, of fermentation lactobacillus, lactobacillus lactic, lactobacillus plantarum, pediococcus acidilactici and bifidobacterium adolescentis are added for synergic fermentation, probiotics liquid vinegar obtained after the fermentation of the fermented vinegar is sterilized, and an appropriate amount of white granulated sugar is added to obtain the fermented vinegar with antioxidant substances. Vinegar residues can be dried to produce the filling materials of pig feed and animal feed. The method has the advantages that the material selection application range of probiotics culture media such as the aspergillus niger, aspergillus oryzae, anaerobic bacteroides, fermentation lactobacillus, lactobacillus lactic, lactobacillus plantarum, pediococcus acidilactici and bifidobacterium adolescentis is greatly widened, the novel fermented vinegar inactivated and fermented by the probiotics is provided for consumers, and the method is rich in raw material source, low in cost, stable in production process, low in production equipment investment, simple to operate, easy to popularize and promising in market application and development prospect.

The invention brings forward biomarkers for end-stage renal disease and an application thereof. The biomarkers for end-stage renal disease are Akkermansia muciniphila, Alistipes finegoldii, Alistipesshahii, Bacteroides fibrobacter, Bacteroides fragilis, Bifidobacterium dentium, Clostridium difficile, Clostridium saccharolyticum, Desulfovibrio Vulgaris, Eggerthella lenta, Enterococcus faecalis, Enterococcus faecium, Flavonifractor plautii, Fusobacterium nucleatum, butyric acid-producing enterobacteriaceae, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus infantarius, Streptococcus thermophilus, butyrate-producing bacteria, Eubacterium rectal and Faecalibacterium prausnitzi. Whether a subject suffers from or is susceptible to end-stage renal disease can be effectively determined by determining these microbial markers in the intestinal flora of the subject.

The present invention discloses paenarthrobacter nicotinovorans and an application thereof in preventing and treating diseases. The microorganism group induction signal quenching bacterium paenarthrobacter nicotinovorans strain D-9 is screened and preserved at Guangdong Culture Collection Center on June 14, 2019, and has a preservation number of GDMCC No.60691. The strain has activity of quenchingquorum sensing signal molecules of N-acyl homoserine lactones (AHLs), besides has stable and significant quenching effect, and thus has huge application potential in preventing and treating harms ofpectobacterium carotovorum subsp. carotovora (Pcc) and other pathogenic bacteria mediated by depending AHLs quorum sensing signals. The anti-pathogenic drug with quorum quenching as a mode of action has broad application prospects.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating hypercholesteremia. Experiments show that bacteroides fragilis is safe, nontoxic and strong in pharmacologic action and has good preventing and treating effect to hypercholesteremia, thereby indicating that the bacteroides fragilis has good edible and officinal prospects. The invention explores novel use of bacteroides fragilis and develops a novel application field. Bacteroides fragilis as probiotic can be used for preparing foods or medical compositions for preventing and treating hypercholesteremia so as to provide a clinically health-care and preventing and treating food suitable for human to take.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to an application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals. The invention explores a novel use of bacteroides fragilis and opens up a novel application field. Experiments show that bacteroides fragilis as a kind of probiotics can be used for preparing animal feed additives to prevent intestinal diseases of animals so as to promote healthy growth of animals.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparation of a composition for treating bacterial vaginitis. The experiments show that bacteroides fragilis is safe and nontoxic and strong in pharmacologic action, and has good treating effect to treat bacterial vaginitis, thereby indicating that the bacteroides fragilis has good edible and medicinal prospects. According to the invention, a novel use of bacteroides fragilis is explored and a novel application field is developed. Bacteroides fragilis as a probiotic can be used for preparing foods or medical compositions for treating bacterial vaginitis.

The invention provides a liquid-solid combined fermentation process for Bacteroides fragilis. The process comprises a first step of preparing a liquid nutrient solution from, by weight, 0.5 to 2.5% of peptone, 0.2 to 0.5% of glucose, 0.001 to 0.5% of cysteine, 0.2 to 0.5% of NaCl, 0.1 to 0.3% of NaHPO4, 0.02 to 0.1% of sodium thioglycolate, 30 to 60% of liquid ox liver extract, 30 to 60% of liquid beef extract and 0.1 to 0.8% of yeast extract. The process provided by the invention employs liquid-solid combined fermentation, and a great amount of Bacteroides fragilis can be obtained in a short period of time by using the process; and the process has the advantages of easiness, small investment, easy controllability in operation, small possibility of infection with competitors due to implementation of all the operations under vacuum and aseptic conditions and high concentration of bacterial strains.

The invention belongs to the biomedical field, in particular to the use of Bacteroides fragilis in the preparation of drugs for the treatment and prevention of tuberculosis. The invention also provides the application of Bacteroides fragilis in the preparation of pharmaceutical compositions, foods, health products and food additives for treating and/or preventing tuberculosis. The Bacteroides fragilis provided by the invention can effectively treat and/or prevent tuberculosis and enhance the immune protection effect of tuberculosis bacillus Calmette-Guerin vaccine (BCG), and has wide application prospect.

The invention discloses a strain of bacteroides vulgatus capable of protecting intestinal permeability and application thereof, and belongs to the technical field of microorganisms. The bacteroides vulgatus CCFM1152 provided by the invention has been preserved in the Guangdong Microbial Culture Collection Centre on November 9, 2020, and the preservation number is GDMCC No.61279. The bacteroides vulgatus CCFM1152 provided by the invention can effectively prevent weight loss and shortened colon length induced by DSS, reduce intestinal permeability and repair colonic mucosa injury. Therefore, the bacteroides vulgatus CCFM1152 has a wide application prospect in the aspect of preparing food and microecological preparations for protecting the intestinal permeability.

The invention discloses application of drug combination of bacteroides fragilis and a PD-1 antibody and/or a PD-L1 antibody in prevention and treatment of tumors of a genitourinary system. A large number of experiments prove that the bacteroides fragilis, especially the bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685, can be used for effectively preventing and treating the tumors of the genitourinary system by regulating immune factors, improving the state of immune cells and enhancing the anti-tumor immune response of a body.

The invention relates to applications of Bacteroides fragilis in animal breeding, particularly to applications of Bacteroides fragilis in prevention and/or treatment of animal gastrointestinal diseases and in pharmaceutical compositions and feed additives, wherein the Bacteroides fragilis is ZY-312 and has the preservation number of CGMCC No.10685. According to the present invention, the Bacteroides fragilis ZY-312 does not contain the enterotoxin gene bft, has significant and high capabilities of cholate resistance and gastric acid resistance compared with the existing Bacteroides fragilis, can effectively prevent and/or treat animal gastrointestinal diseases, improves animal immunity and disease resistance, reduces animal prevalence, improves animal feed conversion rate, increases animal weight, promotes growth and development and production performance, can reduce the use of antibiotics, does not produce drug resistance, further has characteristics of safety and no toxicity, can improve the quality of products such as meat, eggs, milk and the like, can eliminate antibiotic drug residues, purify mew environment, and protects ecological environment.

The invention discloses an application of a bacteroides vulgarus probiotic strain in preparation of a lipid-lowering medicine. The strain is named as bacteroides vulgarus during preservation and is preserved in China General Microbiological Culture Collection Center on January 7, 2019, with an accession number being CGMCC No. 17140. The strain is harmless to animals, and has the blood fat regulating effects of remarkably reducing low-density lipoprotein, total cholesterol and triglyceride and increasing high-density lipoprotein.

The invention discloses application of drug combination of bacteroides fragilis zwitterionic capsular polysaccharide and a PD-1 antibody and/or a PD-L1 antibody in prevention and treatment of respiratory system tumors. A large number of experiments prove that the bacteroides fragilis zwitter-ion capsular polysaccharide, especially the zwitter-ion capsular polysaccharide extracted from bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685, and the PD-1 antibody/PD-L1 antibody are combined for use, so that the immune cell proportion and the immune factor level can be adjusted, the anti-tumor immune response of a body is enhanced, and the respiratory system tumors are effectively prevented and treated.

The invention relates to a novel application of Bacteroides fragilis and an immune checkpoint inhibitor. The invention relates to application of a combination of bacteroides fragilis and an immune checkpoint inhibitor in preparation of a medicine for preventing and treating lymphoma. The preservation number of the bacteroides fragilis is CGMCC No.10685. Compared with the prior art, the invention has the following beneficial effects: a large number of experiments prove that the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685 is combined with an immune checkpoint inhibitor for use, especially a PD-1 inhibitor for use, so that the Bacteroides fragilis ZY-312 has a synergistic effect on lymphoma.

The invention discloses a method for detecting influence of dietary fiber on activity of human intestinal bacteria in the field of bacterial activity detection. The method comprises the detection of bacteroides, and comprises the following specific steps: 1, preparing a bacteroides culture medium; 2, culturing the bacteroides until the bacteroides reaches a logarithmic phase, collecting the bacteroides, washing the bacteroides by using the bacteroides culture medium, and diluting bacteroides bacterial liquid by using the bacteroides culture medium until the OD600 value is 0.2 to 0.23; 3, in a96-pore plate, adding 100 microliters of diluted bacteroides bacterial liquid and 100 microliters of dietary fiber solution into each pore correspondingly, so that the bacterial concentration OD600 ineach pore is 0.09 to 0.11; culturing in a 37-DEG C constant-temperature anaerobic incubator for 72 hours, and recording the OD600 value every 12 hours; and 4, drawing a growth curve of the bacteroides under the action of the dietary fiber according to the OD600 value of the bacteroides recorded at each time point. According to the scheme, the bacteroides culture medium is optimized, so that the growth state of the bacteroides in the culture medium is more fit with the growth state of the bacteroides in a human intestinal tract, and the accuracy of a detection result is improved.

The invention discloses an aniline high-efficiency degradation microbial agent, a preparation method thereof and application of the aniline high-efficiency degradation microbial agent in chemical wastewater. The aniline high-efficiency degradation microbial agent mainly comprises alcaligenes faecalis, microbacterium bacteroides distasonis and lysine bacillus. The aniline degrading microbial agentcan grow by taking aniline as a unique carbon source and a unique nitrogen source, and can degrade 1000mg/L of aniline to 50mg/L or below, and the removal rate reaches 95% or above; the microbial agent prepared by the invention is added into wastewater according to a certain amount, contains a plurality of microorganisms with excellent degradation capability on aniline, and has a good degradationeffect on aniline polluted water, so that the problem that aniline is difficult to biologically solve is solved.

The invention discloses an anaerobic facultative probiotic symbiotic metabolic enzyme preparation. The preparation comprises the following components in parts by mass of 10-14 parts of clostridium which is a group of gram-positive bacteria and can generate spores, and the diameter of the spores is greater than the width of thalli, so that the thalli are expanded to be fusiform, and 12 to 18 partsof clostridium acetobutylicum, 12 to 18 parts of clostridium ljungdahlii, 12 to 18 parts of clostridium thermocellum, 8 to 12 parts of clostridium saccharobutyricum, 10 to 14 parts of clostridium septicum, 12 to 17 parts of frankia, 8 to 12 parts of salt-tolerant bacillus, 15 to 25 parts of bacteroides polymorphus, 15 to 22 parts of bacillus, 10 to 14 parts of streptomyces, 10 to 16 parts of ruminococcus, 12 to 18 parts of phosphokinase, 13 to 18 parts of acetyl coenzyme, 6 to 10 parts of acetyltransferase, 10 to 14 parts of phosphopyruvate hydratase, 10 to 15 parts of phosphodikinase, 11 to 18 parts of dehydrogenase, 10 to 14 parts of hydroxybutyryl coenzyme, 4 to 6 parts of hydroxybutyryl, 12 to 18 parts of acetyl, 12 to 18 parts of pyruvic acid, and 15-22 parts of phosphoric acid. The invention discloses a sludge treatment method. The preparation is simple to dewater in sludge treatment and degrades harmful substances, so that the sludge treatment is low in cost, pollution-free andlow in energy consumption.

The invention provides novel application of bacteroides fragilis zwitterionic capsular polysaccharide or/and modified zwitterionic capsular polysaccharide. Mainly relates to application of the capsular polysaccharide extract of bacteroides fragilis in preparation of anti-anxiety drugs, the preservation number of the bacteroides fragilis is CGMCC NO.10685, and the capsular polysaccharide extract is an extract of capsular polysaccharide A. The invention further relates to application of the capsular polysaccharide extract of bacteroides fragilis in preparation of anti-anxiety drugs. Compared with the prior art, the invention has the following beneficial effects: the inventor of the invention finds that the capsular polysaccharide A extract of Bacteroides fragilis ZY312 has an obvious effect on anxiety disorder, and the effect is verified by carrying out elevated cross maze behavioral determination and open field experiments on a rat model.

The invention discloses a probiotic candidate strain. The preservation number of the probiotic candidate strain is CGMCC NO.21251, the preservation date is November 26, 2020, the preservation classification name of the probiotic candidate strain is Bacteroides doreiXR2020 (B. dorei XR2020), and the preservation unit is China General Microbiological Culture Collection Center (CGMCC). The strain is harmless to animals and has a remarkable effect of improving clinical symptoms of influenza A. The invention further discloses application of the strain and thallus components thereof in preparation of drugs for preventing and treating influenza A.

The invention relates to a novel application of bacteroides fragilis capsular polysaccharide A and an immune checkpoint inhibitor, and mainly relates to an application of the bacteroides fragilis capsular polysaccharide A and the immune checkpoint inhibitor in preparation of drugs for preventing and treating lymphoma. A large number of experiments prove that when the capsular polysaccharide A of bacteroides fragilis and the immune checkpoint inhibitor are combined for use, the synergistic effect on lymphoma can be achieved.